Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 65 (1987), S. 959-966 
    ISSN: 1432-1440
    Keywords: Metastatic breast cancer ; Hormone monotherapy ; Tamoxifen ; Medroxyprogesterone acetate ; Aminoglutethimide ; Remission rates and duration ; Survival times
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary We analyzed the results of clinical studies on the therapeutic efficacy of hormone monotherapy with tamoxifen, medroxyprogesterone acetate, and aminoglutethimide in metastatic breast cancer, which were published between 1971 and 1986 and involved altogether 7000 patients. The overall response rates in patients treated with these hormonal single agents at various dose levels ranged from 31%–42%. When only estrogen receptor-positive patients were considered, the response rates lay between 41% and 54% in groups which were treated with the antiestrogenic agents tamoxifen or aminoglutethimide. The duration of remission was 12 months for tamoxifen- and aminoglutethimide-treated women, whereas medroxy-progesterone acetate effected remissions lasting from 6–16 months. The overall mean survival from start of therapy in tamoxifen- and aminoglutethimide-treated groups was 20 months, whereas information concerning this therapeutic parameter was available only in a minority of medroxyprogesterone acetate-treated groups. With respect to the response by site of metastatic lesions, all three agents caused a significantly higher degree of remissions in the soft tissue as compared to visceral disease.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Journal of cancer research and clinical oncology 95 (1979), S. 83-86 
    ISSN: 1432-1335
    Keywords: 2-Chloroethylnitrosoureas ; Carcinogenesis ; Rat ; 2-Chloroethylnitrosoharnstoffe ; Carcinogenese ; Ratte
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Nach Heilung der akuten Rattenleukämie L 5222 bei 79 BD IX Ratten mit einmaligen Dosen von 1,3-bis(2-Chloroethyl)-1-nitrosoharnstoff (BCNU) oder 1-(2-Hydroxyethyl)-3-(2-Chloroethyl)-3-nitrosoharnstoff (Hydroxyethyl-CNU) entwickelten sich bei insgesamt 9 Tieren (∼ 11%) sekundäre Malignome.
    Notes: Summary After cure of rat leukemia L 5222 in 79 BD IX rats by single doses of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 1-(2-hydroxyethyl)-3-(2-chloroethyl)-3-nitrosourea (Hydroxyethyl-CNU) a total of 9 rats (11%) developed secondary malignomas.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Journal of cancer research and clinical oncology 114 (1988), S. 183-185 
    ISSN: 1432-1335
    Keywords: Cytotoxic chemotherapy ; First line ; Second line ; Metastatic breast cancer ; Overall survival
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The results of clinical studies dealing with first and second line chemotherapy of metastatic breast cancer published between 1975 and early 1986 which involved 9350 women were reviewed. Our special aim was to evaluate combination chemotherapy and its influence on overall survival in late stage breast cancer patients. No significant improvement in overall survival times was found in this selected group of patients who were treated with intense palliative chemotherapy.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Springer
    Journal of cancer research and clinical oncology 101 (1981), S. 243-248 
    ISSN: 1432-1335
    Keywords: Autochthonous (primary) myeloid leukemia ; Chloroleukemia ; Rat ; Chemotherapy ; Autochthone (primäre) myeloische Leukämie ; Chloroleukämie ; Ratte ; Chemotherapie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary After injection of 15 mg/kg ethylnitrosourea (ENU) weekly for 15 weeks to adult male Wistar rats (total dose: 225 mg/kg) about 10% of the animals developed myeloid leukemias (chloroleukemias), which resemble the chronic myeloid leukemia in man (CML) (peripheral blood picture, tissue infiltration, chronic course as compared to immature-cell rat leukemias). Monotherapy with busulfan effected no remissions. The median survival time after daily treatment with busulfan was 29.5 days (range: 7–70); it was significantly shorter than that of untreated controls (median: 47.5 days, range: 22–81). After weekly application of 20 mg/kg and 50 mg/kg Cyclophosphamide the median survival time increase to 69.5 (range: 26–114) and 61.5 (range: 20–92) days, respectively. Rate and duration of remissions after repeated weekly single doses of cyclophosphamide were positively correlated with the increase in single dose; the high dose-intermittent treatment with 50 mg/kg CPA/week yielded complete remissions in all treated animals. Despite these remissions, however, no significant increase in survival time could be observed in comparison with untreated controls. The comparability of autochthonous chloroleukemias in the rat with human CML is discussed.
    Notes: Zusammenfassung Nach wöchentlicher Injektion von 15 mg/kg Äthylnitrosoharnstoffüber 15 Wochen in erwachsene männliche Wistar Ratten (Gesamtdosis: 225 mg/kg) entwickelten etwa 10% der Tiere Chloroleukämien, die eine auffallende Ähnlichkeit mit der chronischen myeloischen Leukämie (CML) des Menschen haben (peripheres Blutbild, Gewebsinfiltration, chronischer Verlauf beim Vergleich mit unreifzelligen Rattenleukämien). Eine Monotherapie mit Busulfan bewirkte keine Remissionen. Nach täglicher Behandlung mit Busulfan lag die mediane Überlebenszeit bei 29,5 Tagen (Spanne: 7–70 Tage) und war somit kürzer als die der unbehandelten Kontrolltiere (mediane Überlebenszeit: 47,5 Tage; Spanne: 22–81 Tage). Nach wöchentlicher Behandlung mit 20 mg/kg sowie mit 50 mg/kg Cyclophosphamid (CPA) stieg die mediane Überlebenszeit auf 69,5 (Spanne: 26–114) bzw. 61,5 (Spanne: 20–92) Tage an. Die Remissionsrate und die Remissionsdauer nach wöchentlich wiederholten Einzeldosen von Cyclophosphamid zeigten eine positive Korrelation zur Höhe der Einzeldosis; so bewirkte eine intermittierende Behandlung mit 50 mg/kg CPA/Woche bei allen behandelten Ratten eine komplette Remission. Trotz der Remissionen konnte jedoch kein signifikanter Anstieg der Überlebenszeit beim Vergleich mit den unbehandelten Kontrollen beobachtet werden. Die Vergleichbarkeit der autochthonen Chloroleukämie der Ratte mit der CML des Menschen wird diskutiert.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...